I. Cil Et Al. , "Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study," TUMORI JOURNAL , vol.108, no.1, pp.19-25, 2022
Cil, I. Et Al. 2022. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. TUMORI JOURNAL , vol.108, no.1 , 19-25.
Cil, I., Kucukarda, A., Atci, M. M., Secmeler, S., Paksoy, N., Ferhatoglu, F., ... Ak, N.(2022). Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. TUMORI JOURNAL , vol.108, no.1, 19-25.
Cil, Ibrahim Et Al. "Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study," TUMORI JOURNAL , vol.108, no.1, 19-25, 2022
Cil, Ibrahim Et Al. "Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study." TUMORI JOURNAL , vol.108, no.1, pp.19-25, 2022
Cil, I. Et Al. (2022) . "Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study." TUMORI JOURNAL , vol.108, no.1, pp.19-25.
@article{article, author={Ibrahim Cil Et Al. }, title={Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study}, journal={TUMORI JOURNAL}, year=2022, pages={19-25} }